GlassScriptPhysician profile
Samaneh Yousefi
NPI 1316513674
$5,185.69
in general payments reported to CMS, 2019-2025
28 companies · $678 in 2025
The $678 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $274 · 2022: $802 · 2023: $1,680 · 2024: $1,752 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,043 · Education: $67.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,043.08 |
| Education | $67.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $765.07 | 2022-2025 | |
| Ucb, INC. | $632.61 | 2023-2025 | Rystiggo, Fintepla, Briviact |
| Neurocrine Biosciences, INC. | $546.61 | 2022-2024 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $484.30 | 2022-2025 | Ultomiris |
| Jazz Pharmaceuticals INC. | $344.31 | 2023-2025 | |
| Lilly USA, LLC | $232.65 | 2022-2024 | Emgality, Kisunla, Amyvid |
| Alnylam Pharmaceuticals INC. | $209.40 | 2021-2024 | Amvuttra |
| Argenx US, INC. | $208.54 | 2023-2025 | Vyvgart Hytrulo |
| Csl Behring | $175.00 | 2023-2025 | Hizentra |
| Kyowa Kirin, INC. | $166.33 | 2023 | Nourianz |
| Sk Life Science, INC. | $165.41 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $145.70 | 2023-2025 | Wainua |
| Teva Pharmaceuticals USA, INC. | $143.49 | 2022-2023 | Austedo Xr |
| Abiomed | $131.83 | 2023 | Impella |
| Edwards Lifesciences Corporation | $131.19 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $125.00 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $105.63 | 2024 | Dojolvi |
| Takeda Pharmaceuticals U.S.A., INC. | $97.02 | 2023-2024 | Hyqvia, Gammagard |
| Janssen Scientific Affairs, LLC | $85.12 | 2022 | |
| Janssen Biotech, INC. | $66.49 | 2025 | |
| Banner Life Sciences, LLC | $40.84 | 2021-2023 | |
| Octapharma USA, INC. | $37.36 | 2023 | Panzyga |
| Scilex Pharmaceuticals INC. | $37.24 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $28.59 | 2023 | Nuedexta |
| Axsome Therapeutics, INC. | $23.80 | 2025 | Symbravo |
| Amylyx Pharmaceuticals, INC. | $22.81 | 2023 | Relyvrio |
| Lundbeck LLC | $18.11 | 2025 | Vyepti |
| Eisai INC. | $15.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samaneh Yousefi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.